All Articles

Biotech firm Cadence Therapeutics seeks to redefine anticoagulation for high-risk patients, but faces a looming ‘going concern’ warning and a competitive landscape rocked by recent trial setbacks.

As open source software becomes ubiquitous, a surge in collaborative security efforts – spearheaded by the OpenSSF – aims to address growing threats, including vulnerabilities in the AI supply chain. Companies like Target are joining the effort.

Ruder Finn’s new AI-powered content creation studio, rf.StoryLab, is pushing boundaries with innovative partnerships. But as AI integration deepens, questions about data privacy and responsible use emerge.

A Dutch biotech firm is leveraging artificial intelligence and cell-free technology to revolutionize hyaluronic acid production, potentially offering a more sustainable and cost-effective alternative to traditional fermentation.

Genius Group’s ambitious ‘Genius City’ project in Bali aims to revolutionize education with AI, blockchain, and a ‘Bitcoin-first’ community. But navigating Indonesian crypto regulations will be key.

Ball Corporation taps supply chain veteran Ronald J. Lewis as its new CEO, signaling a strategic focus on operational efficiency and sustainability amid shifting market demands and a robust packaging industry.

For nearly four decades, Project SHARE has bridged the gap between financial hardship and essential utilities for Georgians. A look at how this unique partnership is evolving to meet growing needs.

Genpact’s partnership with Celonis is driving significant value for clients through scaled AI deployments. This award recognizes a strategy shifting from pilot projects to enterprise-wide transformation.

A new cybersecurity framework for drones and robotics aims to address escalating threats and meet stringent new Department of Defense requirements, potentially reshaping the future of unmanned systems security.

Australian biotech Vaxxas is poised to revolutionize vaccine delivery with its innovative HD-MAP technology. A new manufacturing facility and positive clinical trial data signal a potential shift in global health access.

Startup Omneky positions itself as more than another AI ad tool, touting an 'AI Creative OS' to streamline generation, testing, and optimization – but can it overcome market fragmentation?

Newzip’s repeat victory at LendingTree’s Innovation Challenge highlights the growing demand for streamlined homebuying experiences and a post-approval bridge between lenders, agents, and borrowers.

A novel initiative is turning Spotify streams and Apple Music downloads into scholarship funds for aspiring artists, backed by a network of prominent philanthropists.

Voyager Therapeutics is streamlining its pipeline, prioritizing new small molecule programs alongside promising advancements in gene therapy delivery, including a novel non-viral platform and a Phase 1/2 Alzheimer's trial.

A strategic investment by ONE Bow River National Defense Fund fuels MotionSafe's mission to erase personal data from connected vehicles, addressing growing privacy and security concerns.

Dycom, a leading telecommunications infrastructure provider, has appointed former Core & Main CEO Stephen LeClair to its board. The move signals a strategic emphasis on operational excellence and potential diversification.

Junior exploration company Aventis Energy is leveraging artificial intelligence to refine exploration at its promising uranium project in Saskatchewan, boosting investor confidence and driving innovation in the sector.

Alzheimer's biotech Acumen Pharma appoints industry veteran George Golumbeski as Chairman ahead of pivotal Phase 2 trial results. Analysts examine the appointment and potential conflicts.

The acquisition aims to fortify emergency communications infrastructure as 911 centers face increasing strain from cyberattacks, aging equipment, and natural disasters. AI-powered solutions are key to the future of emergency response.

A fresh influx of funding and promising clinical data fuels 4D Molecular Therapeutics' efforts to revolutionize treatment for age-related macular degeneration, diabetic macular edema and cystic fibrosis with innovative gene therapies.